News Lilly forges a $415m ALS alliance with UK biotech Alchemab Eli Lilly has added another candidate to a growing pipeline of therapies for ALS, tapping Alchemab for an antibody sourced from 'resilient' patients.
R&D Turning drug development on its head In episode 98 of the pharmaphorum podcast , host Jonah Comstock and Alchemab CEO Young Kwon discuss innovative new routes to drug discovery